Anebulo Pharmaceuticals
Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for acute cannabinoid intoxication and related disorders. Leveraging advanced research and a commitment to addressing unmet medical needs, Anebulo’s lead product candidate, ANEB-001, is designed to counteract the effects of cannabinoid overdose. The company’s pipeline aims to provide effective solutions for patients and healthcare providers facing the challenges of cannabinoid intoxication. With a science-driven approach and dedication to improving patient outcomes, Anebulo Pharmaceuticals is positioned at the forefront of cannabinoid therapeutics, striving to deliver safe and effective pharmaceutical options that address growing public health concerns.
